vaccine

(redirected from Lyme disease vaccine)
Also found in: Dictionary, Medical, Encyclopedia.
Related to Lyme disease vaccine: LYMErix
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for vaccine

Synonyms for vaccine

immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies

References in periodicals archive ?
19, 1999--Rubin-Ehrenthal and Associates (RE&A), the consumer division of Healthworld Corporation, (NASDAQ: HWLD) has announced that a major direct-to-consumer advertising campaign for LYMErix(TM) Lyme disease vaccine from client SmithKline Beecham, began yesterday.
To the Editor: The recent article by Meltzer and colleagues (1) is an :important contribution to a pertinent public health issue: who should receive the newly licensed Lyme disease vaccine.
Decorin Binding Protein has always shown promise as a second generation Lyme disease vaccine candidate in that it actively targets the disease-causing bacterium, B.
Kravitz recommends that people who are at high risk for tick exposure consider getting a Lyme disease vaccine, this would include people who work outside or spend lots of time outdoors in high-risk counties.
Although experiments have shown that a Lyme disease vaccine using rOspA is safe and immunogenic in both animals and humans (17-23), no data have been published concerning the decrease in antibody levels over more than 20 months (9).
April 13 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota announced today that it will cover the Lyme Disease vaccine, LYMErix(TM), using established guidelines adopted by the Minnesota Department of Health.
We are continuing to advance our RSV and Lyme disease vaccine programs and anticipate that our partner, Pasteur Merieux Connaught, will have begun clinical trials of both of these vaccines by mid 1999.
that as a Lyme disease vaccine candidate, DBP may provide advantages
MedImmune is developing a Lyme disease vaccine which is being evaluated in Phase I clinical trials and is collaborating with investigators at Texas A&M on a new vaccine candidate.
Several vaccines under development by MedImmune, including a Lyme disease vaccine beginning clinical trials, employ recombinant BCG technology.
The vaccine, called LymeVax, was the first Lyme disease vaccine developed for any species, including humans, when it was introduced in 1990.
Companies developing Lyme disease vaccines have already expressed an interest in such models, he adds.